"The U.S. Food and Drug Administration today approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma, a form of cancer located in the region where the esophagus joins the stomach./"...
Other adverse reactions are:
Allergic: Generalized allergic reactions.
Psychiatric: Hallucinations, depression, apprehension, nervousness, confusion, nightmares.
Second nonlymphoid malignancies, (including lung cancer, acute myelocytic leukemia and malignant myelosclerosis), and azoospermia have been reported in patients with Hodgkin's disease treated with procarbazine in combination with other chemotherapy and/or radiation. The risks of secondary lung cancer from treatment appear to be multiplied by tobacco use.
Read the Matulane (procarbazine) Side Effects Center for a complete guide to possible side effects
See WARNINGS section.
No cross-resistance with other chemotherapeutic agents, radiotherapy or steroids has been demonstrated.
Read the Matulane Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 12/29/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Matulane Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.